Two of FDA's top cancer regulators to depart

The exits highlight the drain on talent at the FDA created by layoffs, uncertainty, and shifts in policy at the agency

March 28, 2025 Check out STAT+

Sponsored By

Don't miss the latest updates to the STAT Breakthrough Device Tracker, including new tests for cancer and Alzheimer's. Thanks for reading and take care this weekend.

Jose Luis Magana/AP STAT+ | Two of FDA's top cancer regulators to depart, heightening worries about drug reviews Deputy directors at the FDA center that oversees the regulation of cancer drugs plan to leave, adding to a flood of top talent in recent months. By Matthew Herper STAT+ | Make America Healthy Again is ringing through statehouses across the U.S. A "perfect storm" of politics leads state lawmakers to tap into RFK Jr.'s unconventional health movement to reform nutrition, food labels, and more. By Sarah Todd and Isabella Cueto New tests for Alzheimer's and cancer get FDA's 'breakthrough' status STAT Breakthrough Device Tracker update includes blood tests for Alzheimer's and an AI chatbot that can digest images and discuss the results with a doctor. By Lizzy Lawrence Adobe STAT+ | Net prices for medicines inched up in last year's fourth quarter after falling a year ago, analysis finds Net prices are likely to decline this year due to the ongoing introduction of biosimilars, particularly for a class of medicines known as TNF. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser